Patents Assigned to The Salk Institute for Biological Studies
  • Publication number: 20170226154
    Abstract: Provided herein are deuterated compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Application
    Filed: April 7, 2017
    Publication date: August 10, 2017
    Applicant: The Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes
  • Publication number: 20170210824
    Abstract: Isolated monoclonal antibodies and or antigen binding fragments thereof are disclosed herein that specifically bind polypeptides comprising a histidine phosphorylated at N3 (3-pHis). Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors and nucleic acids are also disclosed. Methods are also disclosed for using these antibodies, such as for detection of polypeptides comprising a histidine phosphorylated at N3 (3-pHis). In some embodiments, the methods can be used to investigate signal transduction pathways.
    Type: Application
    Filed: July 1, 2015
    Publication date: July 27, 2017
    Applicants: Salk Institute for Biological Studies, Sanofi
    Inventors: Tony Hunter, Stephen Rush Fuhs, Jill Meisenhelder, Jacques Mauger, Fahad Al-Obeidi, Robert A. Binne
  • Publication number: 20170202893
    Abstract: Recombinant adenoviruses that selectively replicate in E2F deregulated tumor cells are described. The recombinant adenoviruses have a genome encoding a modified E1A protein, a modified or deleted E4orf1 protein, a modified or deleted E4orf6/7 protein, or any combination thereof, such that the recombinant adenoviruses exhibit replication defects in normal cells compared to tumor cells. In some instances, the recombinant adenovirus genomes encode additional modifications that target the recombinant adenoviruses to specific cell types, detarget the viruses from the liver, inhibit viral replication in the liver, and/or evade pre-existing neutralizing antibodies.
    Type: Application
    Filed: March 24, 2017
    Publication date: July 20, 2017
    Applicant: Salk Institute for Biological Studies
    Inventors: Clodagh O'Shea, Shigeki Miyake-Stoner
  • Publication number: 20170189485
    Abstract: This application provides methods of increasing vascularization, muscle performance, muscle rehabilitation, and/or mitochondrial activity in subjects in need thereof, by administering a therapeutically effective amount of one or more agents that increases ERR? activity to the subject. Such agents can include one or more ERR? agonists. In some examples the method does not require that the subject exercise, and as such, the subject may be sedentary (such as bedridden or in a wheelchair).
    Type: Application
    Filed: January 17, 2017
    Publication date: July 6, 2017
    Applicant: Salk Institute for Biological Studies
    Inventors: Vihang A. Narkar, Michael Downes, Ruth T. Yu, Ronald M. Evans
  • Patent number: 9696297
    Abstract: Provided herein are methods and compositions useful in treating neurological disorders.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: July 4, 2017
    Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Maria C. N. Marchetto, Fred H. Gage, Alysson R. Muotri
  • Publication number: 20170157212
    Abstract: Disclosed is a polypeptide that includes amino acids 183-222 of CRIF, wherein the polypeptide does not include the full length CRIF1 amino acid sequence. Also disclosed is a nucleic acid molecule encoding this polypeptide, vectors including this nucleic acid molecule, and host cells transformed with these vectors. In some embodiments, methods are disclosed for treating a subject with cancer, comprising administering to the subject a therapeutically effective amount of an inhibitor of CDK12/CRIF1 interaction, thereby treating the cancer in the subject. In specific non-limiting examples, these methods can utilize CRIF1 polypeptides, nucleic acids encoding these polypeptides, and vectors including these nucleic acids.
    Type: Application
    Filed: December 2, 2016
    Publication date: June 8, 2017
    Applicant: Salk Institute for Biological Studies
    Inventors: Katherine Jones, Seung Hyuk Choi
  • Publication number: 20170129947
    Abstract: The present disclosure provides methods for modulating the interaction between a TAM ligand and a lipid membrane containing phosphatidyl serine (PtdSer). In one example, such methods use a TAM receptor agonist having a PtdSer-containing lipid bilayer membrane with Gas6 and/or Protein S bound to the membrane to activate signaling from one or more TAM receptors and treat an autoimmune disease. In another example, methods are provided for treating a subject with a pathological condition characterized by overactivation of TAM signaling and/or reduction in Type I IFN response, such as infection by an enveloped virus, by use of agents that decrease the interaction between a TAM ligand and PtdSer. Also provided are methods for classifying a virus as susceptible to anti-TAM therapy. Methods of identifying an agent that blocks virus infectivity are also provided.
    Type: Application
    Filed: September 20, 2016
    Publication date: May 11, 2017
    Applicants: Salk Institute for Biological Studies, Kolltan Pharmaceuticals, Inc.
    Inventors: Greg E. Lemke, Lawrence C. Fritz, Benedikt Vollrath, Carla V. Rothlin
  • Publication number: 20170087189
    Abstract: The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for the treatment of type 1 diabetes, type 2 diabetes, or a related disorder.
    Type: Application
    Filed: November 22, 2016
    Publication date: March 30, 2017
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: RONALD M. EVANS, EIJI YOSHIHARA, MICHAEL R. DOWNES, RUTH T. YU, ANNETTE R. ATKINS
  • Publication number: 20170073649
    Abstract: The present invention relates to methods for producing polyketide synthase variants, and for altering the activity and/or substrate specificity of putative native and variant polyketide synthases. The present invention further relates to compositions comprising said polyketide synthase variants, compounds prepared using said polyketide synthase variants, and uses of said polyketide synthase variants. In one embodiment, said polyketide synthase variant is 2-pyrone synthase.
    Type: Application
    Filed: March 5, 2015
    Publication date: March 16, 2017
    Applicants: SALK INSTITUTE FOR BIOLOGICAL STUDIES, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: JOSEPH NOEL, KATE WOODS, MARIANNE BOWMAN, GORDON LOUIE, NANCY ANDERSON DA SILVA, JAVIER PASCUAL CARDENAS
  • Publication number: 20170066724
    Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
    Type: Application
    Filed: September 12, 2016
    Publication date: March 9, 2017
    Applicants: Salk Institute for Biological Studies, The University of Sydney
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Thomas J. Baiga, Ruth T. Yu, John F.W. Keana, Christopher Liddle
  • Publication number: 20170056475
    Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.
    Type: Application
    Filed: November 14, 2016
    Publication date: March 2, 2017
    Applicant: Salk Institute for Biological Studies
    Inventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
  • Publication number: 20170037117
    Abstract: The disclosure features compositions and methods for treating a metabolic disorder, including diabetes, conditions associated with inhibition of insulin secretion, or for increasing longevity. In some embodiments, the methods comprise administering an anti-CGRP antagonist antibody.
    Type: Application
    Filed: October 11, 2016
    Publication date: February 9, 2017
    Applicants: Salk Institute for Biological Studies, The Regents of the University of California, Labrys Biologics, Inc.
    Inventors: Andrew Dillin, Celine Riera, Corey Goodman
  • Patent number: 9546379
    Abstract: The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for the treatment of type 1 diabetes, type 2 diabetes, or a related disorder.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: January 17, 2017
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Eiji Yoshihara, Michael R. Downes, Ruth T. Yu, Annette R. Atkins
  • Publication number: 20160376279
    Abstract: Novel FXR agonists are disclosed, embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
    Type: Application
    Filed: September 12, 2016
    Publication date: December 29, 2016
    Applicants: Salk Institute for Biological Studies, The University of Sydney
    Inventors: Ronald M. Evans, Michael Downes, Thomas J. Baiga, John F.W. Keana, Christopher Liddle
  • Publication number: 20160354440
    Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.
    Type: Application
    Filed: August 18, 2016
    Publication date: December 8, 2016
    Applicant: Salk Institute for Biological Studies
    Inventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
  • Publication number: 20160331760
    Abstract: The present disclosure provides compositions that include a nanoparticle and a compound that reduces the biological activity of one or more bromodomain and extra-terminal family member (BET) proteins (e.g., a bromodomain inhibitor), and methods of using such compounds to increase retention or storage of vitamin A, vitamin D, and/or lipids by a cell, such as an epithelial or stellate cell.
    Type: Application
    Filed: August 2, 2016
    Publication date: November 17, 2016
    Applicant: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes, Mara Sherman, Ning Ding
  • Publication number: 20160289651
    Abstract: This disclosure relates to methods and compositions useful for the treatment of cancer and diseases and disorders associated with autophagy.
    Type: Application
    Filed: February 24, 2016
    Publication date: October 6, 2016
    Applicant: Salk Institute for Biological Studies
    Inventors: Reuben J. Shaw, Daniel F. Egan, Maria Mihaylova, David Shackelford
  • Patent number: 9446097
    Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: September 20, 2016
    Assignee: Salk Institute for Biological Studies
    Inventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
  • Patent number: 9428811
    Abstract: Provided herein are methods of characterizing the epigenetic signature of human induced pluripotent stem cells. The methods are useful in identifying human induced pluripotent stem cells (hiPSCs), diagnostic markers for incomplete hiPSCs reprogramming, and characterization of the efficacy of different reprogramming techniques.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: August 30, 2016
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Joseph R. Ecker, Ryan Lister
  • Publication number: 20160237133
    Abstract: The present disclosure provides chimeric proteins having an N-terminus coupled to a C-terminus, wherein the N-terminus comprises an N-terminal portion of fibroblast growth factor (FGF) 2 and the C-terminus comprises a portion of an FGF1 protein. Such FGF2/FGF1 chimeras can further include a fibroblast growth factor receptor (FGFR) 1c-binding protein, a ?-Klotho-binding protein, or both. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.
    Type: Application
    Filed: April 6, 2016
    Publication date: August 18, 2016
    Applicant: Salk Institute for Biological Studies
    Inventors: Jae Myoung Suh, Michael Downes, Ronald M. Evans, Annette Atkins